Adagene Drug Shows Stronger Tumor Response at Higher Dose in Early Cancer Trial

Adagene said early clinical trial results showed that its experimental cancer drug, muzastotug, worked better at higher doses when combined with Merck's Keytruda.

Merck granted EU approval of Keytruda combo in ovarian cancer

Merck (MRK) announced on Thursday that the European Commission approved its anti-PD-1 therapy Keytruda in combination with chemotherapy (paclitaxel) as a late-line option for certain adults with ...

Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth

Merck (NYSE:MRK) received European Union approval for KEYTRUDA in combination regimens for adults with platinum-resistant ...

Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...
CURE

FDA Approves PD-L1 Test to Guide Keytruda Use in Esophageal and GEJ Cancer

U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...

Merck announces another pricy purchase ahead of Keytruda deadline

Merck headquarters in Rahway, NJ. RAHWAY, N.J. - Merck is spending $6.7 billion to bolster its cancer drug portfolio. That's ...

Merck braces for Keytruda patent loss with $6.7 billion Terns bet

By Siddhi Mahatole March 25 (Reuters) - Merck said on Wednesday it would buy biotech firm Terns Pharma for $6.7 billion, as ...
Idaho Statesman

Insurance denies woman’s cancer treatment, saying it’s not advanced enough | Opinion

Ada County Highway District Commissioner Patricia Nilsson is scheduled to begin chemotherapy on Friday, with or without Keytruda, a drug that her doctor recommends but her health insurance company has ...